Soluble BDCA-2 as a potential biomarker for rheumatoid arthritis and its role in enhancing interferon (IFN)-α production through nucleic acid binding
Authors' conclusion
These findings show that solBDCA-2 enhances type I interferon production by forming immunostimulatory complexes with DNA and RNA.
Study context
- Population
- Patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and healthy controls (serum); pDC line CAL-1 and human PBMCs
- Participants
- 14 / 14 / 15
- Comparison
- Serum solBDCA-2 and IFN-α in RA and SLE vs healthy controls
- RAn = 14
- SLEn = 14
- Healthy controlsn = 15reference
- Outcome
- Serum solBDCA-2 and IFN-α (ELISA) as biomarker for RA and/or SLE
Methodological detailscase-control serum analysis, in vitro
- Case-control serum analysis
- In vitro
Main finding
As reported in the abstract
- IFN-α upregulated in sera of both RA and SLE
- solBDCA-2 upregulated only in RA serum, not in SLE
- solBDCA-2 formed complexes with CpG-ODN 2006 (TLR9 ligand) and poly I:C (TLR3 ligand) that enhanced type I IFN production in CAL-1 cells and human peripheral blood mononuclear cells (hPBMCs)
Original publication
Soluble BDCA-2 as a potential biomarker for rheumatoid arthritis and its role in enhancing IFN-α production through nucleic acid binding. Rheumatology (Oxford). Published 16 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →